Capital Advisors Ltd’s BioXcel Therapeutics BTAI Stock Holding History

Capital Advisors Ltd’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	–	–	1399
2024 Q1	$0	Buy	+2	New	+$95	﹤0.01%	1370

Other funds holding BTAI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Advisors Ltd's BTAI Position: Q2 2024 in Review

Capital Advisors Ltd sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 2 shares.

Capital Advisors Ltd first reported a position in BTAI in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

Capital Advisors Ltd reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
Capital Advisors Ltd sold 2 BioXcel Therapeutics shares in Q2 2024.
Capital Advisors Ltd first reported a position in BioXcel Therapeutics in Q1 2024 and held it in 1 quarter.
Capital Advisors Ltd's BioXcel Therapeutics position peaked at $0 in Q1 2024.
74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.